Is Utah Medical Products, Inc. (UTMD) Overvalued?
We dive into why Utah Medical Products, Inc. (UTMD) could be considered overvalued on 2026-08-18, based on AAII’s Value Score and Grade.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Rosalio Madrigal
Michael Rose
Tudor Pop
| Share Statistics | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $216.9 | $383.9 | 29% |
|
| Shares Out (Mil) | 3.2 | 40.6 | 11% |
|
| Institutional Ownership | 90.7% | 83.3% | 59% |
|
| Float (Mil) | 2.8 | 35.1 | 7% |
|
| Beta | 0.39 | 0.90 | 22% |
|
| Avg Daily Volume (000s) | 39 | 323 | 27% |
|
| Price Change (52-week) |
19.8% | 62.8% | 69% |
|
| Growth | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (1.8%) | 11.8% | 14% |
|
| Net Income (5yr) | 0.9% | (5.6%) | 41% |
|
| EPS (5yr) | 3.4% | 10.6% | 36 |
|
| Dividends (5yr) | 1.8% | 0.0% | 83% |
|
| Cash Flow (5yr) | (18.6%) | (15.6%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $141 | 17% |
|
| Net Income (TTM) (Mil) | $11 | ($10) | 46% |
|
| EPS (TTM) | $3.284 | ($0.400) | 79% |
|
| Operating Cash Flow (TTM) (Mil) | $12 | ($2) | 39% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $1 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $25 | 12% |
|
| Enterprise Value (Q1) (Mil) | $132 | $381 | 23% |
|
| Valuation | UTMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.78 | 2.46 | 49% |
|
| P/E | 20.8 | 28.0 | 55% |
|
| Dividend Yield | 1.8% | 0.0% | 74% |
|
| PEG (5yr hist) | 6.1 | 1.4 | 90% |
|
| Ratios | UTMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.7% | 59.3% | 70% |
|
| Net Margin | 30.5% | (6.9%) | 89% |
|
| ROA | 8.5% | (12.1%) | 83% |
|
| ROE | 8.8% | (10.3%) | 53% |
|
| Liabilities to Assets | 2.0% | 47.2% | 1% |
|
| F-Score | 7 | 4 | 82% |
|
Passing Stock Screens
As of 10/30/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 6.4% |
| +/- S&P 500: | -1.0 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors